CytoMed Therapeutics Limited
$1.02
▼
-4.06%
2026-04-21 07:02:01
w2.cytomed.sg
NCM: GDTC
Explore CytoMed Therapeutics Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.07 M
Current Price
$1.02
52W High / Low
$3.68 / $0.73
Stock P/E
—
Book Value
$0.43
Dividend Yield
—
ROCE
-33.09%
ROE
-50.28%
Face Value
—
EPS
$-0.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
-0.21
Debt / Equity
7.04
Current Ratio
5.17
Quick Ratio
5.17
Forward P/E
-6.67
Price / Sales
13.74
Enterprise Value
$10.52 M
EV / EBITDA
-2.73
EV / Revenue
12.23
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 2. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 3. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 4. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 5. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 6. | Vir Biotechnology, Inc. | $11.09 | — | $1.72 B | — | -52.69% | -45.73% | $10.94 / $4.16 | $5.49 |
| 7. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.32 M | 0.07 M | 0 M | 0 M |
| Operating Profit | -4.24 M | -3.13 M | -3.84 M | -1.86 M |
| Net Profit | -3.98 M | -2.52 M | -4.13 M | -3.13 M |
| EPS in Rs | -0.34 | -0.21 | -0.35 | -0.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.98 M | 10.07 M | 12.37 M | 5.23 M |
| Total Liabilities | 1.13 M | 1.02 M | 1.12 M | 4.64 M |
| Equity | 6.54 M | 8.97 M | 11.25 M | 0.59 M |
| Current Assets | 3.66 M | 6 M | 10.1 M | 2.49 M |
| Current Liabilities | 0.71 M | 0.61 M | 0.72 M | 4.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.7 M | -2.71 M | -3.53 M | -1.4 M |
| Investing CF | 0.93 M | 1.13 M | -2.73 M | -0.47 M |
| Financing CF | 0.21 M | -0.06 M | 10.92 M | 0.97 M |
| Free CF | -4.4 M | -4.2 M | -3.59 M | -1.87 M |
| Capex | -0.7 M | -1.49 M | -0.06 M | -0.47 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 39.11% | -31.99% | — | — |
| Profit Margin % | -3621.1% | — | — | — |
| Operating Margin % | -4504.29% | — | — | — |
| Gross Margin % | 75.37% | — | — | — |
| EBITDA Margin % | -3116.77% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.